Sanofi’s innovative treatment for exposed atopic dermatitis
New survey sheds light on treatment and management of atopic dermatitis (AD) in adolescents.
Dermatologists and doctors have called for an integrated approach to alleviating the physical and psychological burdens of adolescent patients.
According to a joint study by Sanofi and Shanghai Daily on the condition of the skin of adolescents, the most common skin symptoms in adolescents are dry, scaly skin, irritation of the skin during seasonal changes and itching.
The survey was released at the fourth China International Import Expo on Saturday. It reached over 1,000 adolescents aged 12 to 17 and found that nearly 40 percent of adolescents surveyed had been diagnosed with eczema or AD, and nearly 70 percent of adolescents with AD suffered from the disease for over a year.
They reported delays in their studies due to recurrent episodes of AD, and were also socially disturbed.
Xu Jinhua, head of the dermatology department at Huashan Hospital affiliated with Fudan University, said the symptoms of AD cause tremendous burden and pain for adolescent patients and their families. Standardized care from physicians as well as greater attention to their emotional demands are needed.
“Adolescence is a critical stage of growth,” he noted. “Moderate to severe atopic dermatitis not only bothers adolescents with physical symptoms such as skin damage and itching, but also affects their quality of life, including school and interpersonal relationships, which can adversely affect their physical health and mental. “
Sanofi presented its innovative treatment for AD Dupixent for the fourth time at the CIIE. Its approval process has been greatly accelerated.
Earlier this year, Dupixent® (dupilumab) was approved in China for adolescents with moderate to severe atopic dermatitis. It is an extension of the indication for Alzheimer’s disease in adults in China and is based on data from a 16-week global clinical trial in adolescents.
The injection prevents widespread suppression of the immune system and is therefore expected to bring revolutionary changes to the treatment of the disease.
It will play an important role in helping young patients to be relieved of physical and psychological burdens.
Dupixent became the first and only biologic drug approved for the treatment of atopic dermatitis in China in June last year, two years ahead of schedule.
It was also included in the national drug reimbursement list after only five months of commercial launch, which has significantly improved its accessibility.
Xu also noted that early diagnosis and treatment of young patients was especially important to help them with their studies and social interactions.
Despite the growing awareness of atopic dermatitis, there is still a lot of room for improvement for standardized care and treatment among physicians and the general public.